Keywords:
Breast, Oncology, MR, MR-Diffusion/Perfusion, Contrast agent-intravenous, Biopsy, Computer Applications-General, Cancer, Neoplasia
Authors:
A. MILON, S. Vandeperre, J. Poujol, E. Kermarrec, A. Bekhouche, I. Thomassin-Naggara; Paris/FR
DOI:
10.26044/ecr2019/C-1363
Conclusion
Our study demonstrates that ultrafast sequence is useful to distinguish malignant from benign lesions with a shorter time to enhancement for breast carcinoma: a lesion that enhances within the first 31seconds after injection has 5.6 times more risk to be a cancer.
Theses results are in line with those previously published (8,10).
ULTRAFAST sequence can not be used alone as 3 breast cancers were missed (2 intra ductal carcinoma and 1 papillary carcinoma) because of a good but not optimal spatial resolution ; explaining why we included a conventional low temporal but high spatial reslution T1W sequence.
Adding the parameter time to enhancement (TTE < 31s) derived from ultra-fast sequence to FAST sequence improves diagnostic value of the BI-RADS classification on abbreviated protocol to reach values issued from full standard protocol with half less acquisition time (7 min 48 sec versus 13 min 54 sec).
In conclusion,
an abbreviated breast MRI protocol combining a FAST protocol and an ULTRAFAST acquisition is a performant method that could lead to better availability of MR imaging.
An ULTRAFAST sequence provide information on early enhancement characteristic (Time To Enhancement < 31sec),
which is a useful parameter for lesion characterization,
decreasing unecessary biopsies.